Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France - 3-year Follow-up

NCT ID: NCT06866002

Last Updated: 2025-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

2011 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-05

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Populations in precarious situations or with low socio-economic status are at greater risk of diabetes and accelerated ageing. Depending on the population studied, the factors that may explain these health inequalities are not unequivocal and remain poorly understood.

Northern France, which is particularly affected by socio-economic disparities, has one of the highest diabetes prevalence rates in mainland France. This is why the researchers wanted to study the clinical, biological, social and behavioral risk factors for the onset of diabetes and accelerated aging in a large population in northern France.

A 2021 study aimed to characterize the population (a majority of whom (55%) suffer from precarious conditions) who came to the Institut Pasteur de Lille for their health check-up, in order to study risk factors to better explain these health inequalities.

This research consisted of a descriptive observational cross-sectional study carried out on 2233 volunteers (main group) over 18 months, and a complementary analytical case-control study involving 216 participants (sub-group).

At present, we are planning a 3-year follow-up of the cohort. Participants will be recontacted for a new health check-up at the Centre d'examen de Santé de l'Institut Pasteur de Lille. At the end of the health check-up, participants will be interviewed by PrévenDIAB study investigators to collect the same data as initially collected, with the exception of some data we deemed unnecessary.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective : To measure changes in fasting glycemic control after 3 years in PrevenDIAB-1 study participants according to socioeconomic status

Primary efficacy endpoint : fasting plasma glucose and Hb1Ac

* Conversion rate of glycemic status (worsening, stable, improving) according to EPICES score
* Prevalence of pre-diabetes/diabetes (T0 and T 3 years) according to EPICES score

Secondary objectivesspecific to the main group :

* Observe the evolution of anthropometric factors such as BMI (weight), waist circumference and various measures of body composition, and determine their role in the evolution of glycemia.
* Observe the evolution of clinical, biological, metabolomic, behavioral and environmental factors, and determine their role in the evolution of glycemia.
* Measure the impact of PrevenDIAB-1 (+/- prevention intervention) on changes in behaviour and health perception according to socio-economic status (has the completion of a health check-up enabled people to resume a course of care and/or raise awareness/engage in prevention?)
* Gather information on subjects' possible participation in preventive actions, define them (type, duration, indication, etc.) and assess their potential impact on risk factors.
* Propose a personalized care pathway for different risk profiles (roadmap defined for people with diabetes or morbid obesity, for example), create a city-hospital link and follow up with subjects by telephone at 6 months to obtain their feedback/opinions on the management of their pathology.

Secondary Objectives specific to the sub-group:

* Measure changes in the following subgroup parameters:

* physical activity
* sleep
* alcohol consumption
* frailty
* arterial stiffness
* cognitive status
* Determine the link with pre-diabetes and diabetes.
* Obtain qualitative data by setting up focus groups on the co-creation of a "space of trust" promoting health empowerment.

* This work will be carried out by a "health and human sciences" post-doc in 2025.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Prediabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Main Group

observational descriptive cohort

Biological analysis, Physical examination and Questionnaires

Intervention Type OTHER

Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.

Sub group

Case control study

Physical examination and Questionnaires

Intervention Type OTHER

In addition to exams for the main group, there will be 2 additional examinations (arterial stiffness) for the patients of the subgroup and others questionnaires.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological analysis, Physical examination and Questionnaires

Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.

Intervention Type OTHER

Physical examination and Questionnaires

In addition to exams for the main group, there will be 2 additional examinations (arterial stiffness) for the patients of the subgroup and others questionnaires.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant in the PrévenDIAB study

Exclusion Criteria

* Subject participating in another clinical study or in a period of exclusion from another study and incompatible with PrévenDIAB-2 follow-up
* Refusal to participate in study
* Scheduling impossible
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Pasteur de Lille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Coralie BERTHIER

Research prevention center manager

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe FROGUEL

Role: STUDY_CHAIR

PhD PRECIDIAB

Matthias VANDESQUILLE

Role: STUDY_DIRECTOR

PhD PRECIDIAB

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Pasteur de Lille, Lille

Hauts de France, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Frédéric BATTEUX, Pr

Role: CONTACT

0320877316

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Frédéric BATTEUX, Pr

Role: primary

0320877316

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A02836-41

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.